Provided by Tiger Fintech (Singapore) Pte. Ltd.

Soligenix, Inc.

2.68
+0.02000.75%
Post-market: 2.680.00000.00%18:27 EDT
Volume:192.77K
Turnover:511.96K
Market Cap:11.49M
PE:-0.63
High:2.78
Open:2.59
Low:2.58
Close:2.66
52wk High:6.23
52wk Low:1.09
Shares:4.29M
Float Shares:3.26M
Volume Ratio:0.16
T/O Rate:5.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.2455
EPS(LYR):-4.9786
ROE:-391.41%
ROA:-90.94%
PB:6.28
PE(LYR):-0.54

Loading ...

BRIEF-Soligenix Announces Publication Describing Long-Term High Temperature Stability Of Protein Subunit Vaccines For Ebola And Related Viruses

Reuters
·
Sep 04

Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses

THOMSON REUTERS
·
Sep 04

Soligenix Inc. Unveils Corporate Presentation Focused on Advancements in Rare Disease Treatment and Robust Pipeline

Reuters
·
Aug 22

Top Midday Gainers

MT Newswires Live
·
Aug 19

BUZZ-U.S. STOCKS ON THE MOVE-Soligenix, BioXcel, GoodRx

Reuters
·
Aug 18

Soligenix Shares Gain 36% on FDA's Orphan Drug Tag for Behcet's Disease Therapy

THOMSON REUTERS
·
Aug 18

Shares of Soligenix Rise 55.8% Premarket on FDA's Orphan Drug Tag for Behcet's Disease Therapy

THOMSON REUTERS
·
Aug 18

BUZZ-Soligenix jumps on FDA's orphan drug tag for Behcet's disease therapy

Reuters
·
Aug 18

Soligenix Inc. Receives FDA Orphan Drug Designation for SGX945 in the Treatment of Behçet's Disease, Securing Seven Years of Market Exclusivity

Reuters
·
Aug 18

FDA Grants Soligenix Orphan Drug Designation for the Treatment of BehÇEt's Disease After Reviewing Recent Phase 2 Clinical Study Results

THOMSON REUTERS
·
Aug 18

BRIEF-Soligenix Inc Receives Nasdaq Notice For Non-Compliance With Equity Requirement

Reuters
·
Aug 16

Soligenix Inc - Receives Nasdaq Notice for Non-Compliance With Equity Requirement - SEC Filing

THOMSON REUTERS
·
Aug 16

Soligenix Inc. Faces Nasdaq Delisting Risk Due to Non-Compliance with Stockholders' Equity Requirement

Reuters
·
Aug 16

Soligenix Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 14

Soligenix Q2 EPS $(0.82) Beats $(0.92) Estimate

Benzinga
·
Aug 14

Soligenix Inc. Reports No Revenue and Increased Net Loss of $2.7 Million in Q2 2025 with EPS of ($0.82)

Reuters
·
Aug 14

Soligenix Announces Recent Accomplishments and Second Quarter 2025 Financial Results

THOMSON REUTERS
·
Aug 14

Press Release: Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results

Dow Jones
·
Aug 14